1-Pyrrolidinecarboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-,1,1'-bis(1,1-dimethylethyl)ester,(2S,2'S)-

Intermediate for Daclatasvir. Daclatasvir (trade name: Daklinza) is a medication used in combination with other medications to treat hepatitis C (HCV). Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A which is critical for HCV viral transcription and translation. Daclatasvir has been approved by the U.S Food and Drug Administration on June 24, 2015.

Specifications

Product Name:                  1-Pyrrolidinecarboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-,1,1'-bis(1,1-dimethylethyl)ester,(2S,2'S)-

Synonyms:                         N/A

CAS Number:                     1007882-23-6

Molecular Weight:            624.7814

Molecular Formula:          C36H44N6O4

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               O=C(N1CCC[C@H]1c1[nH]cc(n1)c1ccc(cc1)c1ccc(cc1)c1c[nH]c(n1)[C@@H]1CCCN1C(=O)OC(C)(C)C)OC(C)(C)C

1-Pyrrolidinecarboxylic acid,2,2'-([1,1'-biphenyl]-4,4'-diyldi-1H-imidazole-5,2-diyl)bis-,1,1'-bis(1,1-dimethylethyl)ester,(2S,2'S)-

  • $207.00
  • Ex Tax: $207.00

Available Options